Mehmet Solakhan

Mehmet Solakhan

Auto-generated profile, based on publicly available information

Mehmet Solakhan

Department of Urology, Bahcesehir University School of Medicine, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2018 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
MSMehmet Solakhan
Mehmet Solakhan
OBOmer Bayrak
Omer Bayrak
EBErsan Bulut
Ersan Bulut

30 October 2019 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
MSMehmet Solakhan
Mehmet Solakhan
SSSerap Ulusam Seckiner
Serap Ulusam Seckiner
ISIlker Seckiner
Ilker Seckiner

1 June 2019 in International braz j urol
Verified
Journal Article
Open access
PDF file
MSMehmet Solakhan
Mehmet Solakhan
HÇHülya Çiçek
Hülya Çiçek
NONuri Orhan
Nuri Orhan
MYMustafa Yildirim
Mustafa Yildirim
Keywords: Prostatic Neoplasms; Oxidative Stress

1 August 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
NBNecla Benlier
Necla Benlier
MSMehmet Solakhan
Mehmet Solakhan
ZYZeliha Yıldırım
Zeliha Yıldırım
VKVildan Kaya
Vildan Kaya
ÖYÖmer Aydın Yıldırım
Ömer Aydın Yıldırım
MYMustafa Yıldırım
Mustafa Yıldırım

1 January 2021 in European Journal of Rheumatology
Verified
Journal Article
Open access
MSMehmet Solakhan
Mehmet Solakhan
BKBünyamin Kısacık
Bünyamin Kısacık
Objective: We believe that IgG4 may have a role in the pathogenesis of Peyronie’s disease (PD), and this role could be particularly beneficial for developing new strategies; therefore, we aimed to investigate the role of IgG4 in PD. Methods: This study included 3 groups with a total of 139 subjects: (I) PD group (n=61), (II) control group (n=48), and (III) benign prostatic hyperplasia (BPH) group (n=30). IgG4 measurement was performed using the enzyme-linked immunosorbent assay. Plaque size, penile curvature, and the presence of concomitant impotence were evaluated in the PD group. Impotence was assessed based on the International Index of Erectile Function (IIEF). Results: A significant difference was observed between the PD and control groups and between the PD and BPH groups with regard to IgG4 levels, while no significant difference was found between the BPH and control groups (p=0.0001, p=0.002, and p=0.07, respectively). The IgG4 levels were significantly higher in the PD than in the other groups. The cutoff value determined between the groups was 87.5, 82, and 31.5, respectively. Mean plaque size was 2.0±1.01 cm, and a significant relationship was found between plaque size and IgG4 concentration (p=0.02). Mean penile curvature was 35.6±25.1°, and a significant relationship was found between penile curvature of >60° and IgG4 concentration (p=0.001). Mean IIEF score was 19 (range, 7-25). Moreover, no significant relationship was found between erectile dysfunction and IgG4 concentration. Penile pain was present in 24 (39.3%) patients with PD. Conclusion: The IgG4 levels were significantly increased in patients with PD, which implies that IgG4 may have a role in the pathogenesis of PD. This finding could be particularly beneficial for developing new strategies. Future studies with larger patient series are needed to substantiate our findings. Cite this article as: Solakhan M, Kısacık B. Is Peyronie's an IgG4-related disease? Eur J Rheumatol 2021; 8(1): 27-30.

5 July 2021 in African Journal of Urology
Verified
Journal Article
Open access
PDF file
MSMehmet Solakhan
Mehmet Solakhan
NBNecla Benlier
Necla Benlier
ZYZeliha Yıldırım
Zeliha Yıldırım
ASAli Ihsan Seran
Ali Ihsan Seran
VKVildan Kaya
Vildan Kaya
MYMustafa Yıldırım
Mustafa Yıldırım
Background: In this study, we aimed to determine which patients will benefit most from TMT treatment, and to evaluate the factors affecting relapse, survival and response to treatment separately. Methods: For the study, patients who presented to our hospital’s outpatient clinic between 2010 and 2020 and were diagnosed with locally advanced (T2-G3) invasive urothelial bladder cancer and treated with gemcitabine concomitantly with radiotherapy following complete TUR were identified. A total of 112 patients with transitional cell bladder cancer invading the muscle were enrolled in the study including 88 (78.6%) males and 24 (21.4%) females. Results: Tumor location was significantly associated with tumor recurrence (p = 0.003). Recurrence at follow-up was significantly associated with the number of tumor foci (p = 0.008). Median duration of follow-up and median progression-free survival were 41.50 months and 65 ± 4.21 (95% CI, 56.74-73.25) months, respectively. Progression-free survival was not statistically significantly associated with neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR) or BMI (p = 0.32, p = 0.47, p = 0.39, respectively), but muscle invasion during follow-up was significantly associated with progression-free survival (p = 0.009). Conclusions: Tumor location, the number of tumor foci, history of multiple transurethral resection surgeries and a NLR ≥ 2.56 were significantly associated with recurrence following Trimodal therapy (TMT). A lower rate of recurrence was observed among patients undergoing early TMT after initial diagnosis. None of the patients treated with trimodal therapy experienced severe adverse effects. Therefore, trimodal therapy is a safe, effective and tolerable therapeutic option with a low rate of recurrence in selected eligible patients.